2019
Cost-minimization study of the percutaneous approach to endovascular aortic aneurysm repair
Hong JC, Yang GK, Delarmente BA, Khera R, Price J, Faulds J, Chen JC. Cost-minimization study of the percutaneous approach to endovascular aortic aneurysm repair. Journal Of Vascular Surgery 2019, 71: 444-449. PMID: 31176637, DOI: 10.1016/j.jvs.2019.03.040.Peer-Reviewed Original ResearchConceptsEndovascular aortic aneurysm repairVascular closure deviceAortic aneurysm repairLength of hospitalizationP-EVARCost savingsProbabilistic sensitivity analysesAneurysm repairSensitivity analysisTwo-way sensitivity analysesCost-minimization studyCost saving strategyEconomic effectsCost parametersMean cost savingsCost differencesPayer perspectiveSurgical site infectionNational Inpatient SampleThoracic EVARResource allocationSaving strategiesBase caseSavingsSummary measures
2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitors